Case report of a renal cell carcinoma patient with acute pancreatitis under both sunitinib and axitinib treatment

Sunitinib and axitinib are oral tyrosine kinase inhibitors (TKI) that is commonly used in the treatment of metastatic renal cell carcinoma (RCC) as it has been shown to improve the progression-free survival of patients compared with sorafenib. Hypertension, palmar-plantar erythrodysesthesia, diarrhe...

Full description

Bibliographic Details
Published in:	Journal of Oncological Sciences
Main Authors:	Utku Oflazoglu, Umut Varol, Ahmet Alacacioglu, Tarik Salman, Necla Demir, Huseyin Salih Semiz, Aziz Karaoglu, Ilhan Oztop
Format:	Article
Language:	English
Published:	Turkish Society of Oncology 2016-08-01
Subjects:	Sunitinib Axitinib Renal cell carcinoma Pancreatitis Side effects
Online Access:	http://www.sciencedirect.com/science/article/pii/S2452336416300267

Similar Items

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
by: Nicolas S. H. Xander, et al.
Published: (2023-06-01)

The use of a new combination of avelumab + axitinib in patients with metastatic kidney cancer in the first line of treatment
by: B. Ya. Alekseev, et al.
Published: (2021-06-01)

Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System
by: Dong Hyuk Kang, et al.
Published: (2023-05-01)

Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
by: Masaki Murata, et al.
Published: (2019-04-01)

Losartan Alleviates the Side Effects and Maintains the Anticancer Activity of Axitinib
by: Ying Fu, et al.
Published: (2022-04-01)

Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast
by: Benjamin Garmezy, et al.
Published: (2024-10-01)

Solvates and Polymorphs of Axitinib: Characterization and Phase Transformation
by: Yinhu Pan, et al.
Published: (2024-10-01)

Design, Synthesis, and Biological Evaluation of Axitinib Derivatives
by: Na Wei, et al.
Published: (2018-03-01)

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
by: Irina Proskorovsky, et al.
Published: (2018-12-01)

UPLC-MS/MS analysis of axitinib and pharmacokinetic application in beagle dogs
by: Hengyu Bi, et al.
Published: (2024-10-01)

Axitinib in metastatic renal cell carcinoma: single center experience
by: Agnieszka Buraczewska, et al.
Published: (2017-01-01)

Adverse drug reactions associated with sunitinib therapy: Characteristics and risk factors
by: Mugoša Snežana, et al.
Published: (2021-01-01)

Axitinib in sequential therapy in metastatic renal cell carcinoma
by: Agata Kuchar, et al.
Published: (2015-05-01)

Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo
by: Zhang BW, et al.
Published: (2022-06-01)

Systemic hypertension with VEGFR inhibitor (axitinib) therapy in cancer patients: A meta-analysis and systematic review of randomized controlled trials
by: Aravind Dilli Babu, et al.
Published: (2024-06-01)

Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)
by: Ibon Gurruchaga Sotés, et al.
Published: (2021-06-01)

Oxidative stress suppression contributes to antiseizure action of axitinib and rapamycin in pentylenetetrazol-induced kindling
by: O. B. Poshyvak, et al.
Published: (2021-04-01)

Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases
by: Shinji Tamada, et al.
Published: (2022-11-01)

The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms
by: Hao Jiang, et al.
Published: (2023-05-01)

Phase Separation Investigation of Axitinib in Supersaturated Solution
by: Jie Xu, et al.
Published: (2024-11-01)

Theoretical investigation of fullerene (C60) as nano carrier for anti-cancer drug Axitinib
by: Saied Jamaladdin Emamjome Koohbanani, et al.
Published: (2024-03-01)

Anti-angiogenic and antioxidant effects of axitinib in human retinal endothelial cells: implications in diabetic retinopathy
by: Francesca Lazzara, et al.
Published: (2024-06-01)

Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients
by: Andrea Boutros, et al.
Published: (2022-12-01)

Exploring the multifaceted antitumor activity of axitinib in lung carcinoids
by: Monica Oldani, et al.
Published: (2024-07-01)

Potential for use sunitinib in pancreatic neuroendocrine tumors
by: A. A. Markovich, et al.
Published: (2019-06-01)

Erosive nappy erythema following sunitinib intake
by: Saoussane Kharmoum, et al.
Published: (2013-02-01)

Is monitoring mean platelet volume necessary in breast cancer patients?
by: Taskaynatan Halil, et al.
Published: (2018-10-01)

A case of hyperammonemia occurring during treatment of metastatic renal cell carcinoma with axitinib
by: Shoichi Kimura, et al.
Published: (2023-07-01)

Complete remission of brain metastases in renal cell carcinoma treated with axitinib after failure with nivolumab and ipilimumab treatment
by: Koichiro Takayama, et al.
Published: (2022-11-01)

Axitinib as a third or further line of treatment in renal cancer: a single institution experience
by: G. Tsironis, et al.
Published: (2020-06-01)

Pazopanib in the treatment of advanced renal cell carcinoma
by: M. I. Volkova, et al.
Published: (2018-11-01)

Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma
by: Kazuyuki Numakura, et al.
Published: (2024-12-01)

Axitinib targets cardiac fibrosis in pressure overload-induced heart failure through VEGFA-KDR pathway
by: Tiantian Jiao, et al.
Published: (2023-11-01)

Evaluation of β-Catenin Inhibition of Axitinib and Nitazoxanide in Human Monocyte-Derived Dendritic Cells
by: Waqas Azeem, et al.
Published: (2021-08-01)

Epithelioid Angiomyolipoma with Tumor Thrombus into Inferior Vena Cava Presurgically Treated with Combination Therapy of Pembrolizumab and Axitinib: A Case Report
by: Kawasoe C, et al.
Published: (2023-10-01)

Intralesional Axitinib Injection Mitigates Hypertrophic Scar by Inhibiting Angiogenesis Pathway: A Preliminary Study in a Rabbit Ear Model
by: Liu C, et al.
Published: (2023-10-01)

Sunitinib resistance in renal cell carcinoma
by: Christudas Morais
Published: (2014-04-01)

A significant response to sunitinib in a patient with anaplastic thyroid carcinoma
by: Enrique Grande, et al.
Published: (2013-01-01)

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
by: Bellesoeur A, et al.
Published: (2017-09-01)

Impaired Retinal Circulation during Axitinib Treatment for Metastatic Renal Cell Carcinoma
by: Masashi Kimura, et al.
Published: (2019-01-01)